Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9636853 | 0.84 | PARP1 (0.44) | PARP1PARP10ACHESLC6A4ITGB3 | |
| SCHEMBL448182 | 0.77 | ACHE (0.46) | ACHE | |
| SCHEMBL29679345 | 0.74 | CYP19A1 (0.59) | CYP19A1TDP1L3MBTL1 | |
| SCHEMBL18321998 | 0.74 | CYP19A1 (0.49) | PARP1PARP10CYP19A1ITGB3ITGA2B | |
| SCHEMBL10686519 | 0.74 | CYP19A1 (0.59) | CYP19A1TDP1L3MBTL1 | |
| SCHEMBL28733931 | 0.74 | CYP19A1 (0.59) | CYP19A1TDP1L3MBTL1 | |
| SCHEMBL10858599 | 0.74 | METAP1 (0.60) | CYP19A1 | |
| SCHEMBL29405721 | 0.74 | CYP19A1 (0.49) | PARP1PARP10CYP19A1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL10853732 | 0.73 | METAP1 (0.63) | — | |
| Iodide SCHEMBL9132621 | 0.73 | CYP19A1 (0.42) | PARP1PARP10CYP19A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | PARP1 1287/4885PARP10 607/4885ACHE 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.